AI assistant
Xbrane Biopharma Share Issue/Capital Change 2020
3128_rns_2020-06-30_c5295a9e-3e51-456a-ad03-361a6aa3fe09.pdf
Share Issue/Capital Change
Open in viewerOpens in your device viewer
Change of number of shares and votes in Xbrane
Xbrane Biopharma AB ("Xbrane" or the "Company") announces changes to the number of shares and votes in the Company. The number of shares and votes in Xbrane have changed following the issue of 11,709 shares during June through exercise of warrants under the incentive program adopted at the annual general meeting 2018.
As of 30 June 2020 the total number of shares and votes in the Company amounts to 19,280,707. The Company's registered share capital amounts to approximately SEK 4,322,465.
About Us
Xbrane Biopharma AB develops biological drugs based on a platform technology that provides significantly lower production costs compared to competing systems. Xbrane's leading product Xlucane, a Lucentis® biosimilar candidate, addresses the €10.4b ophthalmic VEGFa inhibitor market. Xlucane is in phase III and marketing authorization is expected mid-2022. Xbrane has additionally four biosimilars in its pipeline targeting €8.7b in originator sales. Xbrane's head office is in Solna, just outside Stockholm. Xbrane is listed on Nasdaq Stockholm under the ticker XBRANE. For more information, visit www.xbrane.com.
This information is information that Xbrane Biopharma is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2020-06-30 08: 00 CEST.